Abstract
Fifteen Alzheimer (AD) and fifteen normative (NM) age-matched autopsy brains were analyzed in superior temporal cortex, hippocampal and brainstem samples. Vascular endothelial growth factor (VEGF) positive capillaries were quantitatively analyzed in all three sites in the 30 cases. Amyloid β42 senile plaques and VEGF positive capillaries were counted and statistically analyzed using Mann-Whitney, Kruskal–Wallis and the non-parametric Spearman’s test. There is a significantly different expression of capillary VEGF between normative and Alzheimer brains. Within Alzheimer’s superior temporal, hippocampus and brainstem sites there was reduced VEGF expression, with the P value being less than 0.05 in all three sites (superior temporal less than 0.035, hippocampus less than 0.001, brainstem less than 0.006). As VEGF is an important endothelial growth factor involved in vascular remodeling, angiogenesis, and endothelial/blood brain barrier maintenance, its reduced expression in Alzheimer’s disease is evidence for altered capillary function in this disease, which may be contributory to its pathogenesis by altering beta amyloid handling and efflux.
Keywords: Alzheimer's disease, blood-brain barrier, senile plaques, VEGF.
Current Neurovascular Research
Title:Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease
Volume: 11 Issue: 3
Author(s): John Provias and Brian Jeynes
Affiliation:
Keywords: Alzheimer's disease, blood-brain barrier, senile plaques, VEGF.
Abstract: Fifteen Alzheimer (AD) and fifteen normative (NM) age-matched autopsy brains were analyzed in superior temporal cortex, hippocampal and brainstem samples. Vascular endothelial growth factor (VEGF) positive capillaries were quantitatively analyzed in all three sites in the 30 cases. Amyloid β42 senile plaques and VEGF positive capillaries were counted and statistically analyzed using Mann-Whitney, Kruskal–Wallis and the non-parametric Spearman’s test. There is a significantly different expression of capillary VEGF between normative and Alzheimer brains. Within Alzheimer’s superior temporal, hippocampus and brainstem sites there was reduced VEGF expression, with the P value being less than 0.05 in all three sites (superior temporal less than 0.035, hippocampus less than 0.001, brainstem less than 0.006). As VEGF is an important endothelial growth factor involved in vascular remodeling, angiogenesis, and endothelial/blood brain barrier maintenance, its reduced expression in Alzheimer’s disease is evidence for altered capillary function in this disease, which may be contributory to its pathogenesis by altering beta amyloid handling and efflux.
Export Options
About this article
Cite this article as:
Provias John and Jeynes Brian, Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease, Current Neurovascular Research 2014; 11 (3) . https://dx.doi.org/10.2174/1567202611666140520122316
DOI https://dx.doi.org/10.2174/1567202611666140520122316 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology The Modulation of Beneficial and/or Harmful Effects of Free Oxygen Radicals in the Context of Molecular Mechanisms Regarding Drug – PART I
Current Topics in Medicinal Chemistry Facial Pain Expression in Dementia: A Review of the Experimental and Clinical Evidence
Current Alzheimer Research Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Brain Perfusion SPECT with Brodmann Areas Analysis in Differentiating Frontotemporal Dementia Subtypes
Current Alzheimer Research Early Life Stress in Depressive Patients: Role of Glucocorticoid and Mineralocorticoid Receptors and of Hypothalamic-Pituitary-Adrenal Axis Activity
Current Pharmaceutical Design Allosteric Modulation of Muscarinic Acetylcholine Receptors
Current Neuropharmacology The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Meet the Editorial Board Member
Current Neuropharmacology SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Association Study of IL-4 -590 C/T and DDX39B -22 G/C Polymorphisms with the Risk of Late-Onset Alzheimer’s Disease in Iranian Population
Current Aging Science Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Current Protein & Peptide Science Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research The Implications of Autophagy in Alzheimer’s Disease
Current Alzheimer Research Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences A Review of Chemical Agents in the Pharmacotherapy of Addiction
Current Medicinal Chemistry Fine Tuning of Intracellular Ca<sup>2+</sup> Content by Pharmacological Agents – A Strategy to Prevent Synapse Loss in Alzheimer Disease Hippocampal Neurons
Current Alzheimer Research